April 21, 2021

Seqster Raises $12M Series A to Accelerate the Adoption of its Healthcare Data Interoperability Technology

““Seqster was built on the foundation that real-time access to a patient’s complete medical history can solve major pain points across the healthcare continuum, impacting lives at scale,” said Ardy Arianpour, CEO and co-founder of Seqster.“

OmniHealth Holdings LLC, Takeda Digital Ventures, 23andMe’s Anne Wojcicki join the growth funding round.

SAN DIEGO, Calif. April 22, 2021: Seqster PDM Inc. (“Seqster”), the leader in patient-centric healthcare data technology, announced today it has raised $12M in a Series A round of venture capital financing. The funding round was led by OmniHealth Holdings LLC, with additional investment from Takeda Digital Ventures and 23andMe’s CEO and Founder, Anne Wojcicki. This investment fuels Seqster’s ability to grow and evolve its technology to meet the demand for its multi-dimensional healthcare data platform.

Seqster provides patient engagement with proprietary technology to access secure, longitudinal, and comprehensive healthcare data in real time, both at the patient level and at scale. This includes electronic health records (EHRs), pharmacy data, lab data, genomic data (DNA), fitness wearables data, and social determinants of health (SDOH).

“Seqster was built on the foundation that real-time access to a patient’s complete medical history can solve major pain points across the healthcare continuum, impacting lives at scale,” said Ardy Arianpour, CEO and co-founder of Seqster. “We are excited to have investors who are experienced operators and who share our mission and vision to change the way an enterprise or a patient can capture, refine and manage a multitude of disparate data sources in real-time, and present that aggregate in a way that solves real healthcare challenges.”

“Seqster is solving one of healthcare’s biggest challenges – siloed data, and they have done so with a solution that is comprehensive, easy to deploy, and scalable,” said Tim O’Donnell, Managing Partner of OmniHealth Holdings. “Seqster has provided significant value in the pharmaceutical world by making it easier to recruit and track clinical trial participants. The company is making significant inroads in the healthcare space, where access to complete longitudinal patient data will lower costs and improve patient outcomes. This new investment will enable the company to expand further into healthcare, where Seqster’s software has numerous applications.”

Seqster was founded in 2016 by Ardy Arianpour, Dr. Xiang Li, and Dana Hosseini to directly address healthcare’s fundamental problem of data silos and fragmented health data. Automated data collection in real-time is even more critical during the COVID-19 pandemic, especially in the clinical trial setting. Leading bio-pharmaceutical companies have been using the Seqster platform for remote clinical trials around the world.



Contact Us

We’d love to hear from you.